Literature DB >> 2127942

Prevalence of hepatitis C in South Africa: detection of anti-HCV in recent and stored serum.

L A Ellis1, D Brown, J D Conradie, A Paterson, R Sher, J Millo, E Theodossiadou, G M Dusheiko.   

Abstract

The prevalence of anti-HCV was studied in a cohort of 2,072 South Africans. The results were compared in selected recently collected sera and in stored sera. The serum ALT and anti-HBc were also studied as surrogate markers in this population. The following groups were tested: (a) 498 urban, black blood donors (b) 500 white blood donors (c) 500 Asian blood donors (d) 216 rural hospitalized patients (e) 358 rural mineworkers. Sera found positive by the original ELISA were retested, and reproducibly positive tests in rural black men (group d) were confirmed both by recombinant immunoblot assay and by a second ELISA. An anti-HCV prevalence of 1.2%, 0.8%, and 0.6% in urban blacks, Asians, and whites was found. Antibodies to hepatitis B core antigen were found in 42.9%, 3.4%, and 1.2% of black, Asian, and white donors, respectively; 76% of donors positive for anti-HCV were anti-HBc negative. In rural African men, 17% of stored serum samples and 9.2% of recently collected serum samples were positive for anti-HCV. In this cohort 3.84% were positive by all three assays. These results suggest that the prevalence of anti-HCV in low and high-risk South African urban blood donors is comparable to high and low prevalence areas in Europe, the United States, and Japan, but indicates a relatively high degree of exposure to hepatitis C in rural African men. The reactivity of stored, frozen sera in this population requires further investigation. In South African urban blood donors, surrogate marker testing will not expedite HCV screening.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2127942     DOI: 10.1002/jmv.1890320410

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV.

Authors:  C L Cherry; J S Affandi; B J Brew; J Creighton; S Djauzi; D J Hooker; D Imran; A Kamarulzaman; P Kamerman; J C McArthur; R D Moore; P Price; K Smyth; I L Tan; S Vanar; A Wadley; S L Wesselingh; E Yunihastuti
Journal:  Neurology       Date:  2010-05-11       Impact factor: 9.910

Review 2.  Viral markers in the treatment of hepatitis B and C.

Authors:  H Schmilovitz-Weiss; M Levy; N Thompson; G Dusheiko
Journal:  Gut       Date:  1993       Impact factor: 23.059

3.  Hepatitis C virus in autoimmune liver disease in the UK: aetiological agent or artefact?

Authors:  B P Rowan; A Smith; D Gleeson; L P Hunt; T W Warnes
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

4.  Prevalence of second generation antibody to hepatitis C virus among voluntary blood donors in Osaka, Japan.

Authors:  H Tanaka; T Hiyama; H Tsukuma; Y Okubo; H Yamano; A Kitada; I Fujimoto
Journal:  Cancer Causes Control       Date:  1994-09       Impact factor: 2.506

Review 5.  Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa.

Authors:  M C Kew
Journal:  Gut       Date:  1996       Impact factor: 23.059

6.  Prevalence and associations with hepatitis B and hepatitis C infection among HIV-infected adults in South Africa.

Authors:  C J Hoffmann; D Dayal; M Cheyip; J A McIntyre; G E Gray; S Conway; N A Martinson
Journal:  Int J STD AIDS       Date:  2012-10       Impact factor: 1.359

7.  The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up.

Authors:  Robert Hecht; Lindsey Hiebert; Wendy C Spearman; Mark W Sonderup; Teresa Guthrie; Timothy B Hallett; Shevanthi Nayagam; Homie Razavi; Shan Soe-Lin; Kgomotso Vilakazi-Nhlapo; Yogan Pillay; Stephen Resch
Journal:  Health Policy Plan       Date:  2018-05-01       Impact factor: 3.344

8.  Aminotransferases are associated with insulin resistance and atherosclerosis in rheumatoid arthritis.

Authors:  Patrick H Dessein; Angela J Woodiwiss; Barry I Joffe; Gavin R Norton
Journal:  BMC Cardiovasc Disord       Date:  2007-10-29       Impact factor: 2.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.